EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

The hepatitis C virus (HCV) is believed to have infected approximately 170 million people worldwide (Fig. 1). Often referred to as the silent killer, patients can remain asymptomatic for decades ...

Under MP version 2 (n = 10), in which ribavirin is avoided and prophylaxis against vasospasm is suggested, survival is estimated to be 20%. Intention-to-treat analyses avoid many biases in ...

No respiratory syncytial virus vaccines are approved for children, and the only available treatment, aerosolized ribavirin, has low efficacy. Ziresovir may offer a new treatment option.

Infection with respiratory syncytial virus (RSV), the cause of annual winter epidemics of respiratory illness in all age groups, is best recognized for being the leading diagnosis in very young ...

While there are some differences between each type, all of them cause dry, flaky, scaly skin, redness, and itching. Eczema is ...

Back then, your treatment options were 26 to 52 weeks of weekly injections of a medication called interferon, usually with an ...

Rodent-borne hantaviruses are associated with two main clinical disorders in humans: hemorrhagic fever with renal syndrome and hantavirus cardiopulmonary syndrome. Although hantavirus diseases can ...

Antiviral therapy: Empirical antiviral treatment with ribavirin is used for viral haemorrhagic fever. This drug inhibits the replication of the virus inside the host, thus leading to a decline in ...

Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin.On 17 May 2017, Natco Pharma announced that its ...